Over the next 2 years, Sanofi will provide $1 million in research funding to support the PD GENEration: Mapping the Future of Parkinson’s Disease initiative.
“With an estimated 10-15% of people with Parkinson’s disease having a genetic form of the disease, people may have risk genes even when they have no apparent family history. Genetic testing is critical for advancing understanding of the biology behind Parkinson’s disease and increasing patient access to clinical trials targeting specific genetic mutations, with the hope of slowing disease progression.
“The PD GENEration study is an exciting platform to facilitate this, and it’s already demonstrating early success.”
— Erik Wallstroem, Therapeutic Area Head, Neurology Development
Genetic testing and counseling through PD GENEration provides people with Parkinson’s disease with detailed knowledge of their genetic status relative to key Parkinson’s-related genes, ultimately empowering them to know more about their own disease. GBA, LRRK2 and SNCA are examples of genes associated with Parkinson’s disease that are included in the PD GENEration test.
Genetic testing can help people with Parkinson’s disease and their physicians identify whether they may qualify for enrollment in certain clinical trials based on their test results. Findings from PD GENEration also will contribute to the biological understanding of the disease, helping researchers assess the impact of each mutation and which ones may cause the disease.
“This collaboration with Sanofi will help us continue to improve Parkinson’s care by helping PD GENEration participants better manage their disease while supporting scientists to better understand Parkinson’s disease.
“We are thrilled to work with Sanofi to empower the Parkinson’s disease community with more information about their diagnosis and potential treatment options.”
— John L. Lehr, President and Chief Executive Officer of the Parkinson’s Foundation
[Source(s): Sanofi, PR Newswire]